Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Although statins are widely prescribed medications, there remains considerable variability in therapeutic response. Genetics can explain only part of this variability. Metabolomics is a global biochemical approach that provides powerful tools for mapping pathways implicated in disease and in response to treatment. Metabolomics captures net interactions between genome, microbiome and the environment. In this study, we used a targeted GC-MS metabolomics platform to measure a panel of metabolites within cholesterol synthesis, dietary sterol absorption, and bile acid formation to determine metabolite signatures that may predict variation in statin LDL-C lowering efficacy. Measurements were performed in two subsets of the total study population in the Cholesterol and Pharmacogenetics (CAP) study: Full Range of Response (FR), and Good and Poor Responders (GPR) were 100 individuals randomly selected from across the entire range of LDL-C responses in CAP. GPR were 48 individuals, 24 each from the top and bottom 10% of the LDL-C response distribution matched for body mass index, race, and gender. We identified three secondary, bacterial-derived bile acids that contribute to predicting the magnitude of statin-induced LDL-C lowering in good responders. Bile acids and statins share transporters in the liver and intestine; we observed that increased plasma concentration of simvastatin positively correlates with higher levels of several secondary bile acids. Genetic analysis of these subjects identified associations between levels of seven bile acids and a single nucleotide polymorphism (SNP), rs4149056, in the gene encoding the organic anion transporter SLCO1B1. These findings, along with recently published results that the gut microbiome plays an important role in cardiovascular disease, indicate that interactions between genome, gut microbiome and environmental influences should be considered in the study and management of cardiovascular disease. Metabolic profiles could provide valuable information about treatment outcomes and could contribute to a more personalized approach to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Active cholesterol metabolites are produced by interspecies biosynthetic pathways. Bile acids are the main metabolites of cholesterol (CHOL). Primary bile acids (blue ovals; cholic acid (CA) and chenodeoxycholic acid (CDCA)) are produced by endogenous enzymes in the liver and are modified by bacteria of the genus Clostridia colonizing the gut to form secondary bile acids (yellow ovals; lithocholic acid (LCA) and deoxycholic acid [18]). Arrows broken by double lines represent multiple enzymatic steps and only the genes encoding the rate limiting enzymes are listed. The bacterial operon baiABCDEFGHI encodes eight enzymes and a bile acid transporter that together form the pathway for synthesis of secondary bile acids. The amino acids glycine and taurine are conjugated to primary and secondary bile acids in the liver by the host encoded bile acid-CoA amino acid transferase (BAAT) to form tauro- and glycolithocholic acid (TLCA, GLCA) and tauro- and glycodeoxycholic acid (TDCA GDCA). Gut bacteria of genus Lactobacillus catalyze the conversion of cholesterol metabolites to coprostanol (COPR) and can limit the intestinal absorption of cholesterol.](https://figures.cochat.ai/paper-figures/9948cbeee5e94e979366d6651fafcaf5/enteric-microbiome-metabolites-correlate-with-response-to-simvastatin-treatment-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In humans, the response to simvastatin treatment (indicated by LDL cholesterol levels) is positively associated with the pretreatment levels of three microbiota-produced secondary bile acids: lithocholic acid, taurolithocholic acid and glycolithocholic acid.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · cited 4×
“recently have implicated enteric bacteria and phosphatidylcholine metabolism in the pathogenesis of cardiovascular disease [15].”
BackgroundInfluentialRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829 · cited 1×
“have suggested that probiotics, by altering intestinal microflora, can alter the enterohepatic circulation of secondary bile acids [36].”
BackgroundMetabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., & Siuzdak, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812874106 · Cited by 2,677 · cited 1×
“Metabolomics can capture a unique portrait of the state and changes of the gut microbiota by direct measurements of metabolite production [12,13,14].”
BackgroundSLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 1×
“The SLCO1B1 transporter is of particular interest because it is known to transport simvastatin from plasma into the liver, and SNP rs4149056 has been associated with statin-induced myopathy in individuals treated with high dose simvastatin [34].”
BackgroundXenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807 · cited 2×
“At the same time simvastatin and bile acids also regulate the expression of these transporters [28,30,31,32].”
BackgroundClayton, T. A., Baker, D., Lindon, J. C., Everett, J. R., & Nicholson, J. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904489106 · Cited by 765 · cited 4×
“It is becoming increasingly clear that gut microbial symbiots are critical for normal digestion and defense, and also play an important role in development of disease [15] and in metabolizing orally ingested therapeutics [12].”
BackgroundInfluentialGut microbiome-host interactions in health and disease
Kinross, J. M., Darzi, A. W., & Nicholson, J. K. (2011) · Genome Medicine · doi:10.1186/gm228 · Cited by 691 · cited 1×
“Metabolomics can capture a unique portrait of the state and changes of the gut microbiota by direct measurements of metabolite production [12,13,14].”
Background
Cited by
Items 101–198 of 198
Yu, Q., Zhao, J., Xu, Z., Chen, Y., Shao, T., Long, X., Liu, Z., Gao, X., Rengel, Z., Shi, J., et al. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.11.010 · Cited by 34
The influence of the intestinal microflora to the efficacy of Rosuvastatin
Wang, L., Wang, Y., Wang, H., Zhou, X., Wei, X., Xie, Z., Zhang, Z., Wang, K., & Mu, J. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0801-x · Cited by 32
Data mining the human gut microbiota for therapeutic targets
Collison, M., Hirt, R. P., Wipat, A., Nakjang, S., Sanséau, P., & Brown, J. R. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbs002 · Cited by 32
Trimethylamine N-oxide in cardiovascular disease: Pathophysiology and the potential role of statins
Latif, F., Mubbashir, A., Khan, M. S., Shaikh, Z., Memon, A., Alvares, J., Azhar, A., Jain, H., Ahmed, R., & Kanagala, S. G. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123304 · Cited by 28
The effect of network biology on drug toxicology
Gautier, L., Taboureau, O., & Audouze, K. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.820704 · Cited by 28
“For example, there are more and more evidence that the gut microbiome plays an important role in cardiovascular disease, indicating that interactions between genome, gut microbiome, and environmental influences should be considered in the drug development process [97] and application of network biology should help in…”
BackgroundDing, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 31
“A study involving plasma metabolomic profiling in 100 human subjects found that baseline concentrations of three secondary bacterial-derived BAs (LCA, taurolithocholic acid, and glycolithocholic acid), positively predicted the magnitude of simvastatin-induced LDLC lowering (Kaddurah-Daouk et al., 2011).”
BackgroundPharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out
Conti, G., D’Amico, F., Fabbrini, M., Brigidi, P., Barone, M., & Turroni, S. (2022) · Genes · doi:10.3390/genes14010055 · Cited by 28
Metabolomics as a tool for Personalizing Medicine: 2012 Update
Sun, J., Beger, R. D., & Schnackenberg, L. K. (2013) · Personalized Medicine · doi:10.2217/pme.13.8 · Cited by 25
She, J., Sun, L., Yu, Y., Fan, H., Li, X., Zhang, X., Zhuo, X., Guo, M., Liu, J., Liu, P., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2415487 · Cited by 24
“77 Dae-Hyoung Yoo et al. found that incubation of lovastatin with human and rat fecal enzyme preparations produced four metabolites, M1 (des-methyl butyryl metabolite), M4 (hydroxylated metabolite), M8 (reactive hydroxy acid metabolite), and M9 (hydroxylated M8), which suggested that the intestinal…”
BackgroundRankin, N., Preiss, D., Welsh, P. I., & Sattar, N. A. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw271 · Cited by 27
“However, the bile acid and simvastatin example demonstrates that this is not always the case.(62,64) Problems with identification will be improved as spectral databases such as MassBank and the Human Metabolome Database (HMDB) continue to grow.”
BackgroundRole of the gut microbiome in cardiovascular drug response: The potential for clinical application
Steiner, H. E., Gee, K., Giles, J. B., Knight, H., Hurwitz, B. L., & Karnes, J. H. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2650 · Cited by 22
Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges
Gianazza, E., Brioschi, M., Iezzi, A., Paglia, G., & Banfi, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043291 · Cited by 24
“A targeted GC-MS sterol and bile acid metabolomics platform also confirmed the potential role of intestinal bile acid metabolism in modulating simvastatin efficacy through effects on tissue transport [64], because a single nucleotide polymorphism (SNP) in the gene encoding a transporter in the liver and intestine (i.”
BackgroundĐanić, M., Pavlović, N., Lazarević, S., Stanimirov, B., Vukmirović, S., Al‐Salami, H., Mooranian, A., & Mikov, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1111115 · Cited by 24
“Additionally, the metabolomics analysis showed that higher pretreatment levels of bacterial derived bile acids correlated with lowdensity lipoprotein cholesterol (LDL-C) lowering in patients who had a good response to simvastatin (Kaddurah-Daouk et al., 2011).”
BackgroundMendelian randomization analysis rules out disylipidaemia as colorectal cancer cause
Ibáñez‐Sanz, G., Díez-Villanueva, A., Riera-Ponsati, M., Fernández‐Villa, T., Fernández‐Navarro, P., Bustamante, M., Llorca, J., Amiano, P., Ascunce, N., Fernández‐Tardón, G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49880-w · Cited by 21
Simvastatin induces human gut bacterial cell surface genes
Escalante, V., Nayak, R. R., Noecker, C. A., Babdor, J., Spitzer, M. H., Deutschbauer, A. M., & Turnbaugh, P. J. (2023) · Molecular Microbiology · doi:10.1111/mmi.15151 · Cited by 22
Microbiome-based companion diagnostics: no longer science fiction?
Raes, J. (2016) · Gut · doi:10.1136/gutjnl-2015-311015 · Cited by 21
The human gut microbiome – a new and exciting avenue in cardiovascular drug discovery
Du, Y., Li, X., Su, C., Wang, L., Jiang, J., & Hong, B. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1638909 · Cited by 21
Role of Gut Microbiome in Atherosclerosis: Molecular and Therapeutic Aspects
Salazar, J., Morillo, V., Suarez, M., Castro, A. V., Ramírez, P., Rojas, M., Áñez, R., D’Marco, L., Chacín, M., & Bermúdez, V. (2023) · Current Cardiology Reviews · doi:10.2174/1573403x19666230202164524 · Cited by 21
“Similarly, both preclinical and clinical studies report that statins can modify GM composition (Table 3 ) [150-159].”
BackgroundModulating the Human Gut Microbiome as an Emerging Therapeutic Paradigm
Rajpal, D. K., & Brown, J. R. (2013) · Science Progress · doi:10.3184/003685013x13691404141587 · Cited by 19
Precarious Symbiosis Between Host and Microbiome in Cardiovascular Health
Bartolomaeus, H., Markó, L., Wilck, N., Luft, F. C., Forslund, S. K., & Müller, D. N. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.11786 · Cited by 19
Pharmacometabolomic signature links simvastatin therapy and insulin resistance
Elbadawi-Sidhu, M., Baillie, R., Zhu, H., Chen, Y. I., Goodarzi, M. O., Rotter, J. I., Krauss, R. M., Fiehn, O., & Kaddurah‐Daouk, R. (2016) · Metabolomics · doi:10.1007/s11306-016-1141-3 · Cited by 18
“We have also published data from the CAP study correlating enteric microbiome metabolites to simvastatin response, identifying three secondary bacterial-derived bile acids that contributed to prediction of beneficial simvastatin response (Kaddurah-Daouk et al. 2011).”
Self-citationHu, L., Hu, B., Zhang, L., Yuhong, H., Zhang, Y., Zhang, R., Yu, H., Liu, D., Wang, X., Lin, O., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1408581 · Cited by 16
Zaidi, S., Ali, K., & Khan, A. U. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03589-7 · Cited by 16
Effect of Gut Microbiota on the Pharmacokinetics of Nifedipine in Spontaneously Hypertensive Rats
Zhou, R., Yang, H., Zhu, P., Liu, Y., Zhang, Y., Zhang, W., Zhou, H., Li, X., & Li, Q. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082085 · Cited by 15
“Secondary bile acids, enteric microbiome metabolites, were positively related to the concentration of simvastatin [15].”
BackgroundTherapeutic manipulation of the microbiome in liver disease
Parthasarathy, G., Malhi, H., & Bajaj, J. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000987 · Cited by 15
Respuesta a las estatinas en prevención cardiovascular: evaluación de los hiporrespondedores
Masson, W. M., Lobo, M., Manente, D., Vitagliano, L., Rostán, M., Siniawski, D. A., Huerin, M. S., & Giorgi, M. A. (2025) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v82.i1.2882 · Cited by 15
Therapeutic implications of the gastrointestinal microbiome
Kashyap, P., & Quigley, E. M. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.004 · Cited by 15
Complex influences of gut microbiome metabolism on various drug responses
Chae, S., Kim, D. J., & Cho, J. (2020) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2020.28.e3 · Cited by 14
Joseph, J., & Loscalzo, J. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0505-x · Cited by 15
Metagenomic Annotation Networks: Construction and Applications
Vey, G., & Moreno‐Hagelsieb, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041283 · Cited by 14
Zhang, J., Zhang, J., Wang, R., & Jia, Z. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666181019145159 · Cited by 14
Mitry, P., Wawro, N., Sharma, S., Kriebel, J., Artati, A., Adamski, J., Heier, M., Meisinger, C., Thorand, B., Grallert, H., et al. (2019) · British Journal Of Nutrition · doi:10.1017/s000711451900103x · Cited by 13
“Cholesterol is also metabolised to coprostanol by intestinal bacteria with a microbial steroid 5β-reductase enzyme (adapted from Kaddurah-Daouk et al. 2011(7)).”
BackgroundHua, S., Ma, C., Zhang, J., Li, J., Wu, W., Xu, N., Luo, G., & Zhao, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00352 · Cited by 13
“, 2005) or the gut microbiome (Kaddurah-Daouk et al., 2011) may play substantial roles.”
BackgroundZhang, S., Lü, Y., Li, H., Han, L., Jing, W., Wu, X., Ullah, S., Liu, R., Wu, Y., & Xu, J. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00252 · Cited by 12
Beebe, K. D., Sampey, B. P., Watkins, S. M., Milburn, M. V., & Eckhart, A. D. (2014) · Clinical and Translational Science · doi:10.1111/cts.12131 · Cited by 14
Self-citationOrganic Anion‐Transporting Polypeptides
Tirona, R. G., & Kim, R. B. (2014) · Wiley eBooks · doi:10.1002/9781118705308.ch4 · Cited by 13
Al‐Busafi, S. A., Alwassief, A., Madian, A., Atalla, H., Alboraie, M. A. A., Elbahrawy, A., & Eslam, M. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i8.108730 · Cited by 11
Chen, Q., Huang, D., Liu, J., Jia, N., Shen, Z., Pei, C., Chen, C., Liu, Y., Wang, Y., Shi, S., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1705487 · Cited by 14
Mehmood, K., Moin, A., Hussain, T., Rizvi, S. M. D., Gowda, D., Shakil, S., & Kamal, M. (2021) · Folia Microbiologica · doi:10.1007/s12223-021-00926-5 · Cited by 12
Clinical applications of pharmacogenetics: Present and near future
Gladding, P. A. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12111 · Cited by 14
Integration of epigenomics and metabolomics: From biomarkers discovery to personalized medicine
Baghel, R., Maan, K., Haritwal, T., & Rana, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85652-2.00002-6 · Cited by 14
Pharmacometabolomics: Current Applications and Future Perspectives
Kim, H. J., & Yoon, Y.-R. (2014) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2014.22.1.8 · Cited by 10
“Pharmacometabolomics for predicting individual drug response Several studies have demonstrated the practical value of pharmacometabolomics in predicting individual drug response and variation.[4-6] A recent study employed a lipidomics platform to develop metabolite signatures that predict individual response to statin…”
BackgroundSilveira, A. M. R., Duarte, G. H. B., Fernandes, A. M. A. P., Garcia, P. H. D., Vieira, N. R., Antônio, M. A., & Carvalho, P. D. O. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752960 · Cited by 10
Gut Microbiota and Metabolic Diseases: From Pathogenesis to Therapeutic Perspective
Burcelin, R., Courtney, M., & Amar, J. (2014) · Molecular and integrative toxicology · doi:10.1007/978-1-4471-6539-2_11 · Cited by 9
“Furthermore, statins, classical anti-dyslipidemic agents prescribed to reduce the incidence of cardiovascular events, have been shown to be associated with microbial-derived agents that could be responsible for the cholesterol-lowering effect, explaining the effi cacy of the treatment [ 246 ].”
BackgroundInterindividual variability in statin pharmacokinetics and effects of drug transporters
Hirota, T., & Ieiri, I. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2305746 · Cited by 10
“A number of studies recently demonstrated a link between the gut microbiome and statin use [36,37].”
BackgroundPharmacometabonomics – the novel way to personalized drug therapy
Maslov, D. L., Balashova, E. E., Lokhov, P. G., & Archakov, A. I. (2017) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20176302115 · Cited by 8
Identification of the Microbiota in the Aging Process
Sarkar, A., & Pitchumoni, C. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00004-5 · Cited by 10
Li, R., Yang, L., Guan, S., Lin, M., Lai, H.-J., Liu, K., Liu, Z., & Zhang, X. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00554 · Cited by 7
Serum cholesterol increase in statin users associated with antibiotic use: Case-crossover study
Lavi, I., & Gronich, N. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175209 · Cited by 7
Pharmacomicrobiomics informs clinical pharmacogenomics
Κάτσιλα, Θ., Balasopoulou, A., Tsagaraki, I., & Patrinos, G. P. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0027 · Cited by 7
Probiotic use in the management of hypertension: A new era of therapeutic management
Nivsarkar, M., Borse, S., Singh, D., Upadhyay, D., & Sharma, V. (2018) · Indian Journal of Health Sciences and Biomedical Research (KLEU) · doi:10.4103/kleuhsj.kleuhsj_3_18 · Cited by 8
“[11,53] For instance, several medications are commonly prescribed to patients with metabolic syndrome, including the antidiabetic drug metformin and the lipid‐lowering drug simvastatin, which were suggested to be modulated by the gut microbiome.[54] Epidemiological data show that HTN patients are more prone to periodo…”
BackgroundAssociation between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease
He, X., Lai, Y., Mo, C., Zhang, Y., Ai, P., Xu, S., Qian, Y., Xiao, Q., & Yang, X. (2024) · Microorganisms · doi:10.3390/microorganisms12071432 · Cited by 7
Metagenomic Cosmid Libraries Suitable for Functional Screening in Proteobacteria
Cheng, J., Lam, K. N., Engel, K., Hall, M., Neufeld, J. D., & Charles, T. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-61510-3_1 · Cited by 6
The Role of Pharmacometabonomics in Predicting Drug Pharmacokinetics
Varshavi, D., Varshavi, D., & Everett, J. R. (2016) · International Journal of Pharmacokinetics · doi:10.4155/ipk-2016-0010 · Cited by 6
Habtemariam, S. (2026) · BioTech · doi:10.3390/biotech15020043 · Cited by 7
“Statins, including simvastatin and rosuvastatin, show variable lipid-lowering efficacy that correlates with gut microbiome composition and bile acid metabolism [72].”
Personalized nutrition, personalized medicine, and microbiome therapeutics
Chauhan, N. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00017-3 · Cited by 13
Li, B., Kwok, L. Y., Wang, D., Li, L., Zhang, H., & Chen, Y. (2025) · Engineering · doi:10.1016/j.eng.2025.04.017 · Cited by 6
Statin therapy and gut microbiota
Chen, P., & Li, K. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001098 · Cited by 5
Pharmacogenetics and Pharmacogenomics
Voora, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800681-8.00016-5 · Cited by 5
Sharma, N., & Roy, S. (2025) · Apmis · doi:10.1111/apm.70100 · Cited by 4
Recent advances and clinical relevance of microbiome dynamics in health and disease
Gavanji, S., Suhail, M., Bencúrová, E., Dandekar, T., & Othman, E. M. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2679197 · Cited by 4
Pharmacometabonomics and Predictive Metabonomics
Everett, J. R., Lindon, J. C., & Nicholson, J. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800344-2.00006-9 · Cited by 4
Ahmed, L. A., & Al‐Massri, K. F. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178210 · Cited by 4
The Emerging Relevance of the Gut Microbiome in Cardiometabolic Health
Obin, M. S., Parnell, L. D., & Ordovás, J. M. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0357-2 · Cited by 3
“Microbiomeinformed treatments are exemplified by the finding that levels of bacterially-derived bile acids predict low density lipoportein cholesterol (LDL-C) lowering by simvastatin and that this is at least partially attributable to alleles at marker rs4149056 in gene SLCO1B1 encoding a statin and bile acid transpor…”
Andreassen, O. A., Desikan, R. S., Wang, Y., Thompson, W. K., Schork, A. J., Zuber, V., Doncheva, N. T., Ellinghaus, E., Albrecht, M., Mattingsdal, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128048 · Cited by 3
“Consequently, alterations in the gut microbiota are likely to influence the regulation of bile acids and lipids metabolism[56], and bacterial derived bile acids predict response of statin treatment in humans[57].”
BackgroundInfluence of intestinal microbiota on the metabolism of main cardiotropic drugs
Stepanov, M. S. (2024) · Perm Medical Journal · doi:10.17816/pmj41554-65 · Cited by 2
Hyperlipidemia and gut microbiota: the role of prebiotics, probiotics, statins and fibrates
Григорьева, И. Н., Тов, Н. Л., & Nepomnyashchikh, D. L. (2025) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20250301 · Cited by 3
Individualizing Pharmacogenomic Test Results in the Context of the Microbiome
Haga, S. B. (2020) · Personalized Medicine · doi:10.2217/pme-2020-0077 · Cited by 2
Pharmacometabolomics in Drug Discovery and Development
Marques, C. F., & Marques, M. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11665-4 · Cited by 2
Future of Statins in Sepsis: A Review on Its Safety and Efficacy
eladwy, S., & Bazan, N. S. (2020) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2020.2001.1022 · Cited by 3
“Simvastatin has been shown to influence gut-derived metabolites which may impact response to the drug, as well as the development of adverse events [72].”
BackgroundPharmacometabolomics-Based Translational Biomarkers: How to Navigate the Data Ocean
Bafiti, V., & Κάτσιλα, Θ. (2022) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2022.0097 · Cited by 2
NMR-based Pharmacometabonomics: A New Approach to Personalized Medicine
Everett, J. R. (2015) · Wiley eBooks · doi:10.1002/9780470034590.emrstm1395 · Cited by 2
Pulmonary research in 2013 and beyond: a National Heart, Lung, and Blood Institute perspective
Kiley, J. P., & Senior, R. M. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00305.2012 · Cited by 2
“A gut cardiovascular axis has been identified by which small molecules ingested are modified by gut organisms into agents that affect the development of atherosclerosis (14, 31).”
BackgroundLi, X., Guo, X., Liu, Y., Ren, F., Li, S., Yang, X., Liu, J., & Zhang, Z. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297713 · Cited by 1
High‐Quality Phenomics are Crucial for Informative Omics Studies
Gurwitz, D. (2012) · Drug Development Research · doi:10.1002/ddr.21025 · Cited by 1
“For omics-reach studies, attention should also be paid to personal gut microbiomes, which may affect individual drug response, as shown for simvastatin [Kaddurah-Daouk et al., 2011].”
BackgroundMikrobiota jelitowa a leki. Interakcje wpływające na skuteczność i bezpieczeństwo farmakoterapii
Nycz, J., & Zajdel, A. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2021-0009 · Cited by 1
“, 2001; 183: 3417-3427 [68] Kaddurah-Daouk R.”
The changes of gut microbiota and metabolites in different drug-induced liver injuries
Zhu, R., Gao, Y., Dong, J., Li, Z., & Ren, Z. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001778 · Cited by 1
Correia, G. D. S. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
The Proximon: Representation, Evaluation, and Applications of Metagenomic Functional Interactions
Vey, G. (2017) · UWSpace (University of Waterloo) · Cited by 2
Xiang, X. (2011) · Helda - University of Helsinki Institutional Repository
Braddock, M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.841139
“Supporting this potential, bacterial-derived metabolites have recently been identified which may correspond to patient response to the LDL lowering drug simvastatin [54].”
BackgroundNn, P., Чепур, С. В., Хурцилава, О. Г., Chubar, O. V., Литвиненко, И. В., Накатис, Я. А., Бакунина, Л. С., Лобеева, А. С., Razumova, D. V., Gogolevsky, A. S., et al. (2018) · Успехи современной биологии · doi:10.7868/s0042132418060078
Hypolipidemic efficacy of probiotic Lactobacillus plantarum in patients with coronary heart disease
Shypulin, V. P., Chernyavsky, V. V., Neverovskyi, A., & Parunian, L. M. (2018) · Ukrainian Therapeutical Journal · doi:10.30978/utj2018-3-4-27 · Cited by 3
Cesur, B., & Dora, D. D. (2020) · European Journal of Therapeutics · doi:10.5152/eurjther.2020.19098
Microbial Drug Interactions and Human Health
Ilhan, Z. E., & Herbst‐Kralovetz, M. M. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160950-00120
If drugs with metabolic action affect the intestinal microbiota. Literature review
Fadieienko, G. D., Gridnyev, O., & Gridneiva, S. V. (2022) · Modern Gastroenterology · doi:10.30978/mg-2022-1-37
Effet du microbiote intestinal sur la pharmaco-onco-immunologie des statines
Pukar, K. C. (2020) · theses.fr (ABES) · doi:10.70675/ff8b34e6z83e6z4a77z8a50z14b3a52080e9
Kulkarni, C. V., Gubatan, J. M. B., Pike, C. W., Hui, G., Gombar, S., Kramer, J. R., Jackson, M. L., Goel, A., Vierling, J., Cholankeril, G. T., et al. (2024) · medRxiv · doi:10.1101/2024.09.17.24313852
“Statins modulate BA profiles directly (via changes in cholesterol synthesis) and indirectly (potentially via modulation of the microbiome) 8,21,22 .”
BackgroundLipid metabolism correction with statins and probiotics
Baryshnikova, N. V., Vm, L., Uspenskiy, Y. P., Suvorov, A. N., & Ермоленко, Е. И. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-229-9-161-174
Gut microbiota impact on drug metabolism, bioavailability, and biotransformation
Boyle, N. R., & Patterson, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29289-7.00019-9
Steiner, H., & Steiner, H. (2022) · UA Campus Repository (The University of Arizona)
Masood, A., Rahim, S. K., Arshad, M. A., Shaikh, N., Saeed, Z. B., Uddin, S. M. A., Zahid, M., Kalim, N., Ahmed, N., & Arshad, M. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i7.1750
Dinu, L.-D., Vamanu, E., & Avram, I. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-95-2104-3_7
Schaefer, L., Cantu, J. O., Demianova, E. A., Scholand, K. K., Pflugfelder, S. C., Britton, R. A., & de Paiva, C. S. (2026) · The Ocular Surface · doi:10.1016/j.jtos.2026.08.005
Zhang, T., Wang, S., Xu, X., & Renjie, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1938639
BindingDB (2019) · UC San Diego · doi:10.7270/q2jd507r
Application of integrative metabonomics in preclinical toxicology to augment drug development
Kadyrov, J. (2026) · Murdoch University Research Portal · doi:10.60867/00000190
Tan, X., Ma, K., Li, X., & Song, C. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1981070
Metadata
- Authors
- Kaddurah-Daouk, R., Baillie, R. A., Zhu, H., Zeng, Z.-B., Wiest, M. M., Nguyen, U. T., Wojnoonski, K., Watkins, S. M., Trupp, M., & Krauss, R. M.
- Affiliations
- Duke Medical Center (US)
- Rosa (United States) (US)
- North Carolina State University (US)
- University of Idaho (US)
- SRI International (US)
- Corresponding author
- Kaddurah-Daouk, Rima
- Krauss, Ronald M.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-10-13
- Volume
- 6
- Issue
- 10
- Pages
- e25482
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3192752
- OpenAlex
- W1998108632
- Cited by
- 193
- References
- 44
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 15 · 2023: 12 · 2022: 13 · 2021: 16 · 2020: 19 · 2019: 12 · 2018: 19 · 2017: 13 · 2016: 14 · 2015: 12 · 2014: 8 · 2013: 17 · 2012: 9
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-05-06)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Washington
- National Heart, Lung, and Blood Institute (U01HL069757)
- National Institute of General Medical Sciences (GM078233, R24GM078233)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- simvastatin, LDL cholesterol lowering, gut microbiota metabolites, secondary bile acids, cholesterol biosynthesis, bile acid transporters, SLCO1B1, rs4149056, pharmacogenetics, metabolomics, personalized treatment, cardiovascular disease
- MeSH terms
- Bile Acids and Salts, Demography, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Models, Biological, Pharmacogenetics, Treatment Outcome, Simvastatin, Polymorphism, Single Nucleotide, Organic Anion Transporters, Liver-Specific Organic Anion Transporter 1, Gastrointestinal Tract, Metagenome, Metabolomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.